Home
About Us
About Us

Scinosen (Shenzhen) Gene Industry Development Co., Ltd. has established a set of large-scale production process and quality control technical standards for recombinant adenovirus products based on the creation of the world's first independently developed gene therapy anti-cancer drug, "Recombinant Human p53 Adenovirus Injection" (also known as "Jinyousheng").

Learn more
Overview

Core team

Business coverage

Business Model

Corporate culture

Qualification Certificate

Intellectual property

Scientific Advisory Board

Scinosen's core assets
CDMO Platform
CDMO Platform

Scinosen (Shenzhen) Gene Industry Group's CDMO platform for viral vector gene drugs, based on its own core intellectual property rights, professional talent team, unique process research and development capabilities, and large-scale production capabilities, provides integrated services ...

Learn more
Platform Introduction

Customized R&D

Customized production

Technical advantages

Scale advantage

Market advantage

Talent advantage

Confidentiality Agreement

Regarding gene carriers

Regarding gene drugs
Products
rAd-p53 "Jinyousheng"

Recombinant human p53 adenovirus injection (Gendice) is a genetically engineered recombinant human p53 gene adenovirus particle (rAd-p53) with infectious activity. It consists of two parts: replication defective human adenovirus type 5 and normal p53 tumor suppressor gene. The replication defective adenovirus particle serves as a carrier to introduce the p53 gene into tumor cells

Learn more
Gendicine

Gendicine Paper Collection
R&D Center
R&D Center

Innovation is the inexhaustible driving force for the development of Sinogene, and the success of Sinogene today stems from relentless independent innovation. Sinogene is committed to the development and industrialization of new gene therapy technologies, and has developed two major technology platforms: the "viral vector gene transduction system" and the "non viral vector gene transduction system".

Learn more
NK/CAR-NK

COVID-19 gene vaccine

P53 gene new drug

P53 biomarker

P53 synergistic immunotherapy

P53 and diabetes

P53 and Heart Disease

P53 and arterial plaque

Insulin glargine

Pipelines
Cooperation
Cooperation

Adhering to the concept of communication and cooperation, continuously improving our own strength, providing customers with higher quality products and services, and making greater contributions to the development of the industry.

Learn more
Kobe University Japan

Shenzhen General Hospital

Southern Medical University Shenzhen Hospital

Manila National Hospital
Health
Health

The science popularization column is carefully crafted by a professional, passionate, and mission driven team. On the path of pursuing a healthy lifestyle, the health science popularization column is like a bright lighthouse, guiding you in the right direction.

Learn more
About GeneTherapy

p53 Gene

Clinical case P53

Genetic testing

Pre cancer intervention

Prevent recurrence and metastasis
News
News report

An important bridge for communication between the company and the outside world. By timely and accurate news releases, customers, partners, investors, and all sectors of society can better understand the latest developments, development strategies, and core values of the company.

Learn more
Company news

Industry news

Media reports
Join Us

Dr.Gao Gui

Author:Scinosen Update time:2024-09-25 Click count:

Dr. Gao is an expert in clinical trials and statistics. He has led the Phase ll/IV clinical trials of Gendicine and the development of dual copy human p53 gene recombinant adenovirus.

Add to Favorites

Previous:Nothing

Next:Dr. Diosdado Bautista

Return to List

Consultation Hotline

(086）0755-33065181

Online Service

9:00-18:00

Dr.Gao Gui

Look around

Product recommendation

About Gendicine

The current application status of rAd-p53

Recombinant human p53 adenovirus injection (Gendicine)